Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ambrisentan
Drug ID BADD_D00100
Description Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. Studies establishing the efficacy of Ambrisentan included patients with both idiopathic or heritable pulmonary arterial hypertension and those with pulmonary arterial hypertension associated with connective tissue diseases. Patients studied displayed symptoms and etiologies predominantly of WHO Functional Class II-III. As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.
Indications and Usage Ambrisentan is indicated for treatment of idiopathic (‘primary’) pulmonary arterial hypertension (IPAH) and pulmonary arterial hypertension (PAH) associated with connective tissue disease in patients with WHO functional class II or III symptoms. In the United States of America, ambrisentan is also indicated in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.
Marketing Status Prescription
ATC Code C02KX02
DrugBank ID DB06403
KEGG ID D07077
MeSH ID C467894
PubChem ID 197712
TTD Drug ID D0X5ZI
NDC Product Code 0591-2405; 16436-0111; 70771-1364; 50137-4051; 61958-0801; 49884-354; 42973-172; 65015-793; 70771-1363; 42794-052; 69097-387; 53104-7702; 61958-0802; 0591-2406; 49884-353; 42794-051; 47335-237; 0378-4270; 14501-0059; 0378-4271; 47335-236; 70710-1179; 70710-1180; 69097-386
Synonyms ambrisentan | (S)-ambrisentan | (+)-(2S)-2-((4,6-dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid | (+)-ambrisentan | LU 208075 | LU-208075 | LU208075 | BSF 208075 | BSF-208075 | BSF208075 | Volibris | ambrisentan, (-)- | (R)-ambrisentan | ambrisentan, (R)- | (-)-ambrisentan | GSK-1325760 | GSK 1325760A | GSK1325760A | GSK 1325760 | GSK-1325760A | GSK1325760 | Letairis | ambrisentan, (+-)- | (+-)-ambrisentan
Chemical Information
Molecular Formula C22H22N2O4
CAS Registry Number 713516-99-5
SMILES CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coma17.02.09.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Cor pulmonale24.08.03.001; 22.06.01.003; 02.05.03.0010.001054%Not Available
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Cough22.02.03.0010.059178%
Crying19.04.02.002; 17.02.05.013; 12.02.11.001; 08.01.03.005--Not Available
Cyanosis24.03.01.007; 22.02.02.007; 02.01.02.0020.002887%
Cyst16.02.02.002; 08.03.05.0010.002021%Not Available
Cystitis20.03.02.002; 11.01.14.0010.004330%
Deafness04.02.01.001--Not Available
Death08.04.01.0010.099856%
Decreased activity19.11.01.002; 08.01.01.006--Not Available
Dehydration14.05.05.001--
Delirium19.13.02.001--
Dementia19.20.02.001; 17.03.01.0010.004041%Not Available
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diabetic ketoacidosis14.07.03.001; 05.07.03.001--Not Available
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.005--Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Diverticulitis11.01.07.003; 07.10.02.001--Not Available
Diverticulum07.10.01.001--Not Available
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.0030.116624%
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 25 Pages